argenx announces results of Annual General Meeting 2016

April 28, 2016

Breda, the Netherlands / Ghent, Belgium – argenx N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that all resolutions presented at the Company's Annual General Meeting were duly passed at the meeting, which was held today at 09:00 CET.

Voting results

All proposed resolutions on the agenda for this annual meeting were approved. The results of the votes will be posted shortly on the Company's website

Changes to the board of directors

Effective today, Dr. P. Klein was appointed to the board of the Company as non-executive director. Dr. P. (Pamela) Klein is an experienced biotech/pharma executive in the field of oncology drug development. Previously she has held a VP position with Genentech; Chief Medical Officer for Intellikine, and Research Director for the National Cancer Institute-Naval Medical Center Breast Center.

Also effective today, Mrs. C. Takke has resigned from the board. Peter Verhaeghe, chairman of the board, commented: "I would like to take this opportunity to thank Christina for her very important and valuable scientific and business strategic contributions as Director over the past years.”

Adoption of 2015 financial statements

Furthermore, the Company's financial statements for the 2015 financial year were adopted by the shareholder meeting. The 2015 financial statements and annual report are available on the company's website.

 

About argenx

argenx combines the diversity of the llama immune system with antibody engineering to advance a clinical pipeline to treat patients with cancer and autoimmune diseases. Our platforms allow us to unlock novel and complex targets and develop antibody-based drugs designed for greater efficacy and longer duration of effect. The strength of our team, our deep understanding of the biology, and our committed collaborations with industry leaders contribute to the success of our journey.

argenx is listed on the Euronext Brussels exchange under the symbol ARGX.

www.argenx.com

SIMPLE Antibody™ and NHance® are trademarks of argenx N.V.

 

For further information, please contact:

Joke Comijn, Corporate Communications Manager

+32 (0)477 77 29 44

+32 (0)9 243 40 70

info@argenx.com

 

Beth DelGiacco (US IR)

Stern Investor Relations

+1 212 362 1200

beth@sternir.com

 

Forward-looking Statements

 

The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “anticipates”, “expects”, “intends”, “may”, “will”, or “should”, and include statements arGEN-X makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. arGEN-X’ actual results may differ materially from those predicted by the forward-looking statements. arGEN-X undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law. “Management’s Discussion and Analysis of Financial Condition and Results of Operations”